Dr. Roman Perez-Soler
Overview
Dr. Roman Perez-Soler currently serves as the Director of Clinical Oncology at the New York University Medical Center, specifically the Kaplan Cancer Center. He specializes in medical oncology and is the principle investigator of the Phase II L-NDDP/Platar trail for the study of pleural mesothelioma. He is internationally considered an expert in experimental cancer treatments receiving a number of awards for his contributions to lung cancer research.
Educational Background
Dr. Perez-Soler graduated with a medical degree from Universidad Autonoma in Barcelona, Spain. He stayed at the Universidad Autonoma to complete his residency and then traveled to the United States to complete his Fellowship in Medical Oncology at the M.D. Anderson Cancer Center in Houston, Texas. He is Board Certified in both Internal Medicine and Medical Oncology. The M.D. Anderson center is dedicated to improving the prognosis for patients in all stages of lung and chest cancers, including mesothelioma.
Professional Highlights
He also holds the position of Chairman of the Department of Oncology at Montefiore Medical Center and Director of the Division of Medical Oncology at the Albert Einstein College of Medicine. At the same institution he serves as the Associate Director for Clinical Research, and Professor of Medicine and Molecular Pharmacology. Dr. Perez-Soler is also Scientific Advisor to Easton Capital Investment Group.
Affiliations, Publications and Clinical Research
Dr. Perez-Soler serves as a member of the Executive Advisory Committee of the General Clinical Research Center. Dr. Perez-Soler has published over a hundred articles, and papers including, "Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib," published in the Cancer Chemother Pharmacol in January of 2009. He also co-authored, "Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK," and "Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene," published in Molecular Pharmacology and the Journal of Thoracic Oncology respectively.
Contact Information
Roman Perez-Soler, M.D.
Montefiore Medical Center
111 East 210th Street
Hofheimer Main, Room 100
Bronx, NY 10467
(718) 920-4001
Source
New York University Medical Center Physician Profile
If you have any questions regarding treatment options or your legal rights, please contact us.
Free Mesothelioma Information Packet
Enter your information to receive a comprehensive mesothelioma packet free of charge at your doorstep within 24 hours.
